Horizons Series: TPMT and NUDT15 Genotyping Recommendations

 TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus 

In this pre-recorded lecture, AMP Pharmacogenomics Working Group members Dr. Reynold Ly moderates as Dr. Makenzie Fulmer provides an update on clinical TPMT and NUDT15 testing, which was recently published online by the JMD. With a goal of promoting standardization of clinical PGx testing across different clinical laboratories, this Working Group has published recommendations on CYP2C19, CYP2C9, Warfarin allele and CYP2D6 genotyping allele selections previously, and now TPMT and NUDT15 selection for clinical laboratories to use as guidelines when designing and developing these PGx assays. Healthcare providers may also find these documents useful in comparing and contrasting PGx tests across clinical laboratories when they are familiar with a “must-test” list for each of the pharmacogenes. Access Practice Guideline here.

• Review TPMT and NUDT15 pharmacogenetics (PGx) and highlight the importance of standardization of clinical PGx and its implications to patient care
• Review the AMP PGx Working Group ‘Tier’ system of PGx sequence variants/alleles recommendation
• Explain the key attributes of Tier 1 and Tier 2 recommended alleles for TPMT and NUDT15 genotyping

Speaker: Makenzie L. Fulmer, PhD Department of Pathology and ARUP Laboratories University of Utah School of Medicine	Moderator: Reynold C. Ly, PhD Indiana University School of Medicine,  Department of Medical and Molecular Genetics

Continuing Education Credit Information

Continuing education credit is no longer available for this webinar

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.